A harmonized and collaborative approach to the clinical testing, scale-up and distribution of candidate vaccines to prevent COVID-19 is essential, scientific leaders write in a perspective published today in Science.
As the COVID-19 pandemic continues, government, industry and academia have introduced a variety of vaccine candidates. The authors note that more than one effective vaccine approach likely will be required to successfully protect the global community from SARS-CoV-2, the virus that causes COVID-19. They describe a strategic approach to research and development that would generate essential data for multiple vaccine candidates in parallel.
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., Lawrence Corey, M.D., professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center in Seattle, and John R. Mascola, M.D., director of NIAID’s Vaccine Research Center are the co-authors of the commentary.
The perspective discusses diverse vaccine candidates and key considerations for development, including the characteristics of various vaccine platforms in terms of prior commercial experience, scalability, and the types of immune responses generated. It also emphasizes that no single vaccine or vaccine platform is likely to meet the global need, highlighting the need for a coordinated strategic approach to vaccine development.
The authors stress that researchers need to learn more about what constitutes a durable protective immune response against COVID-19. They review considerations for vaccine efficacy trials, explaining how trials for several candidate vaccines can be conducted in parallel to generate essential safety and efficacy data and accelerate the licensure and distribution of COVID-19 vaccines. The authors propose specific approaches to harmonizing the clinical testing of multiple vaccine products, including using common clinical trials designs, clinical endpoints, standardized immune assays and a common Data Safety and Monitoring Board.
The authors emphasize that developing COVID-19 vaccines will require unprecedented cooperation from governments, academic institutions, industry, and global philanthropic partners. The ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership spearheaded by NIH aims to facilitate such collaboration with discussions and collaborations on trial designs and data sharing.
Protecting the entire global community from COVID-19 through vaccination will require significant manufacturing capacity, according to the authors. They emphasize the need to fund the necessary biomanufacturing infrastructure and note possible hurdles in the eventual delivery of vaccines, including cost, distribution systems and cold chain requirements. The authors conclude that strategic collaboration among public and private sectors to effectively accelerate COVID-19 vaccine development is essential.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Fauci ‘Cautiously Optimistic’ Coronavirus Vaccine Will Be Available to Public by 2021on June 23, 2020 at 11:59 am
Dr. Anthony Fauci, chief medical advisor for the Trump administration's coronavirus task force, said Tuesday that he is "cautiously optimistic" that a vaccine for the coronavirus will be available to ...
- Watch live: Dr. Anthony Fauci optimistic about COVID-19 vaccine, he and health officials say Trump didn’t ask to slow down testingon June 23, 2020 at 11:59 am
With coronavirus cases rising in about half the states, Dr. Anthony Fauci returns to Capitol Hill on Tuesday at a fraught moment in the nation's pandemic response.
- Two doses of Oxford University’s coronavirus vaccine boosts immune response in pigson June 23, 2020 at 11:50 am
The Pirbright Institute, working in collaboration with the University of Oxford, announced on Tuesday that two doses of an experimental COVID-19 vaccine successfully produced a greater antibody ...
- Will There Be A Coronavirus Vaccine In 2020? Fauci Weighs In On Potential Treatment, Timelineon June 23, 2020 at 11:49 am
Fauci told a House committee he's confident a vaccine will be developed soon, saying it's a matter of "when not if." ...
- Coronavirus Vaccine News: French, US Biotech Companies Expand Partnership, Will Evaluate COVID-19 Candidateson June 23, 2020 at 10:45 am
Sanofi is also developing potential coronavirus vaccines with English pharmaceutical company GlaxoSmithKline Plc.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Robert Durst Loses Coronavirus Mistrial Bid in Murder Caseon June 23, 2020 at 12:15 pm
A Los Angeles judge denied a request for a mistrial in the murder case against New York real estate heir Robert Durst after a three-month delay from the coronavirus outbreak ...
- New York Primary Faces Ballot Problems, While Low Voter Turnout Expected Amid Coronaviruson June 23, 2020 at 12:14 pm
New Yorkers trickled into the polls Tuesday to vote in an array of primary races, but turnout was expected to be low with many people opting for absentee ballots to avoid the spread of the new ...
- Coronavirus kills Florida 17-year-old, marking youngest COVID-19 death in stateon June 23, 2020 at 12:03 pm
A 17-year-old Florida resident has become the state’s youngest coronavirus-related death, according to state health data.
- Coronavirus: German outbreak sparks fresh local lockdownson June 23, 2020 at 12:02 pm
One area is home to a meatpacking plant where more than 1,500 workers have tested positive. State premier Armin Laschet said the "preventative measures" in Gütersloh district would last until 30 June.
- What Did Trump Say About Coronavirus Testing? After Staff Claims He Was 'Joking,' Trump Gives His Own Versionon June 23, 2020 at 11:59 am
President Trump has contradicted the claims of his administration, asserting that he was serious in his comments about COVID-19 testing.